Loading clinical trials...
Loading clinical trials...
Phase I/II Study of Reduced Toxicity Myeloablative Conditioning Regimen for Wiskott-Aldrich Syndrome
Conditions
Interventions
Fludarabine, Busulfan, Thymoglobulin
Locations
1
South Korea
Seoul National University Hospital
Seoul, Chongno-gu, South Korea
Start Date
February 1, 2007
Primary Completion Date
March 1, 2012
Completion Date
March 1, 2012
Last Updated
July 14, 2014
NCT01852370
NCT03837483
NCT00909363
NCT03399461
NCT01347346
NCT01289847
Lead Sponsor
The Korean Society of Pediatric Hematology Oncology
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions